Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909734 | 0.85 | NR1H2 (0.48) | SCDTBK1ALOX5JAK1 | |
| SCHEMBL4908379 | 0.81 | IKBKB (0.52) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL9692152 | 0.81 | CCNB2 (0.46) | MAPK14ALDH1A1MAPK11SMN1; SMN2AURKA | |
| SCHEMBL4906902 | 0.81 | ADORA2B (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4910535 | 0.81 | MEN1 (0.53) | SMN1; SMN2 | |
| SCHEMBL17645693 | 0.78 | AURKA (0.63) | ALOX5AURKAPARP1 | |
| SCHEMBL4939133 | 0.78 | PTGS2 (0.49) | MAPK14PTGS1PTGS2AURKAJAK2 | |
| SCHEMBL4909647 | 0.77 | KDM4E (0.47) | TBK1MAPK14ALDH1A1ALOX5CSNK1A1 | |
| SCHEMBL4909019 | 0.76 | RHEB (0.57) | MAPK14ALDH1A1ALOX5MAPK11SMN1; SMN2 | |
| SCHEMBL4909757 | 0.75 | CCNB2 (0.43) | MAPK14MAPK11PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1934217-A1 | NEW COMPOUNDS II | Astra Zeneca AB (SE) | 2008-06-25 | — | — | EP | claimed |
| WO-2007040439-A1 | NEW COMPOUNDS II | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1934217-A1 | NEW COMPOUNDS II | Astra Zeneca AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007040439-A1 | NEW COMPOUNDS II | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040439-A1 | NEW COMPOUNDS II | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255106-A1 | Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, PYGB, GSK3A | SCD 1996/4885TBK1 301/4885MAPK14 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.